NCT04721535View on ClinicalTrials.gov

A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

PHASE3TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

September 23, 2021

Study Completion Date

October 6, 2021

Conditions
Covid19SARS-COV-2 Infection
Interventions
DRUG

DWJ1248

Orally, 1 tablet of DWJ1248 TID, up to 14 days

DRUG

Placebo

Orally, 1 tablet of placebo TID, up to 14 days

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT04721535 - A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2 | Biotech Hunter | Biotech Hunter